These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 23050813)

  • 1. Thymosin α1 continues to show promise as an enhancer for vaccine response.
    Tuthill C; Rios I; De Rosa A; Camerini R
    Ann N Y Acad Sci; 2012 Oct; 1270():21-7. PubMed ID: 23050813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymosin alpha1. SciClone Pharmaceuticals.
    Billich A
    Curr Opin Investig Drugs; 2002 May; 3(5):698-707. PubMed ID: 12090542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of thymosin alpha-1 (Zadaxin) as a co-adjuvant in influenza vaccines: a review.
    Panatto D; Amicizia D; Lai PL; Camerini R; De Rosa A; Gasparini R
    J Prev Med Hyg; 2011 Sep; 52(3):111-5. PubMed ID: 22010537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymosin-alpha 1 (Zadaxin) enhances the immunogenicity of an adjuvated pandemic H1N1v influenza vaccine (Focetria) in hemodialyzed patients: a pilot study.
    Carraro G; Naso A; Montomoli E; Gasparini R; Camerini R; Panatto D; Tineo MC; De Giorgi L; Piccirella S; Khadang B; Ceracchi M; De Rosa A
    Vaccine; 2012 Feb; 30(6):1170-80. PubMed ID: 22178096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Jack of all trades: thymosin α1 and its pleiotropy.
    Romani L; Moretti S; Fallarino F; Bozza S; Ruggeri L; Casagrande A; Aversa F; Bistoni F; Velardi A; Garaci E
    Ann N Y Acad Sci; 2012 Oct; 1269():1-6. PubMed ID: 23045964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulatory and enhanced antitumor activity of a modified thymosin α1 in melanoma and lung cancer.
    Wang F; Li B; Fu P; Li Q; Zheng H; Lao X
    Int J Pharm; 2018 Aug; 547(1-2):611-620. PubMed ID: 29933059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naïve ferrets.
    Baras B; de Waal L; Stittelaar KJ; Jacob V; Giannini S; Kroeze EJ; van den Brand JM; van Amerongen G; Simon JH; Hanon E; Mossman SP; Osterhaus AD
    Vaccine; 2011 Mar; 29(11):2120-6. PubMed ID: 21238573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot study of thymosin alpha1 therapy for chronic hepatitis B patients.
    Arase Y; Tsubota A; Suzuki Y; Suzuki F; Kobayashi M; Someya T; Akuta N; Hosaka T; Saitoh S; Ikeda K; Kobayashi M; Kumada H
    Intern Med; 2003 Oct; 42(10):941-6. PubMed ID: 14606705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymosin α1 plus routine treatment inhibit inflammatory reaction and improve the quality of life in AECOPD patients.
    Jia Z; Feng Z; Tian R; Wang Q; Wang L
    Immunopharmacol Immunotoxicol; 2015; 37(4):388-92. PubMed ID: 26250523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The anti-tumor efforts of thymosin alpha1 on tumor lysate-pulsed dendritic cells in colon cancer in vitro and in vivo].
    Ma YL; Zheng Z; Li BD; Xie SJ; Li GX; Yan QH; Cai JH
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Nov; 23(11):1046-9. PubMed ID: 17988589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical studies with IRX-2 and thymosin alpha1 in combination therapy.
    Naylor PH; Hadden JW
    Ann N Y Acad Sci; 2010 Apr; 1194():162-8. PubMed ID: 20536465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo study of thymosin alpha1 biodegradable in situ forming poly(lactide-co-glycolide) implants.
    Liu Q; Zhang H; Zhou G; Xie S; Zou H; Yu Y; Li G; Sun D; Zhang G; Lu Y; Zhong Y
    Int J Pharm; 2010 Sep; 397(1-2):122-9. PubMed ID: 20650309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Pediatr Infect Dis J; 2014 Dec; 33(12):e320-9. PubMed ID: 24978857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.
    Radosević K; Rodriguez A; Mintardjo R; Tax D; Bengtsson KL; Thompson C; Zambon M; Weverling GJ; Uytdehaag F; Goudsmit J
    Vaccine; 2008 Jul; 26(29-30):3640-6. PubMed ID: 18514980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thymosin α1 as a stimulatory agent of innate cell-mediated immune response.
    Serafino A; Pierimarchi P; Pica F; Andreola F; Gaziano R; Moroni N; Zonfrillo M; Sinibaldi-Vallebona P; Garaci E
    Ann N Y Acad Sci; 2012 Oct; 1270():13-20. PubMed ID: 23050812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunopharmacology of thymosin alpha1 and cytokine synergy.
    Naylor PH; Quadrini K; Garaci E; Rasi G; Hadden JW
    Ann N Y Acad Sci; 2007 Sep; 1112():235-44. PubMed ID: 17567942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity in Swine of Orally Administered Recombinant Lactobacillus plantarum Expressing Classical Swine Fever Virus E2 Protein in Conjunction with Thymosin α-1 as an Adjuvant.
    Xu YG; Guan XT; Liu ZM; Tian CY; Cui LC
    Appl Environ Microbiol; 2015 Jun; 81(11):3745-52. PubMed ID: 25819954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thymosin-alpha1 modulates dendritic cell differentiation and functional maturation from human peripheral blood CD14+ monocytes.
    Yao Q; Doan LX; Zhang R; Bharadwaj U; Li M; Chen C
    Immunol Lett; 2007 Jun; 110(2):110-20. PubMed ID: 17532057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-range study of MF59-adjuvanted versus nonadjuvanted monovalent A/H1N1 pandemic influenza vaccine in six- to less than thirty-six-month-old children.
    Block SL; Ruiz-Palacios GM; Guerrero ML; Beygo J; Sales V; Holmes SJ
    Pediatr Infect Dis J; 2012 Jul; 31(7):e92-8. PubMed ID: 22481427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.